Daptomycin Chemical Properties
Melting point 202-204 C
Fp 87℃
storage temp. Store at -20°C
solubility methanol: soluble5mg/mL
color colorless to faint yellow
λmax 260nm(EtOH)(lit.)
Merck 14,2823
Safety Information
RTECS HB5626000
Toxicity LD50 i.v. in mice: 600 mg/kg (Debono)
MSDS Information
Daptomycin Usage And Synthesis
Antibiotic Daptomycin is a kind of cyclic lipopeptide antibiotics with novel structure. It is extracted from the Streptomyces fermentation broth. It was discovered by Eli Lilly Company in the 1980s, and successfully developed in 1997 by Cubist Pharmaceuticals. It not only having a novel chemical structure but also has mode of action which is different from any antibiotic approved before: it inhibits cell by disrupting the transport of amino acids through cell membrane, thereby blocking the cell wall peptidoglycan biosynthesis and changing the nature of the cell membrane. It can destroy the bacterial cell membrane function in many aspects, and quickly kill gram-positive bacteria. In addition to the role of taking effect on most clinically relevant gram-positive bacteria, more importantly, Daptomycin has a potent efficacy in treating isolated strains which have shown signs of resistance to methicillin, vancomycin and linezolid. This property is of great clinical significance to patients suffering from severe infection.
In September 2003, the US Food and Drug Administration had approved for the first time that daptomycin could be applied for the treatment of severe skin infections. In March 2006, it was approved for treating infectious diseases.
In January 2006, it is approved by European Commission for the treatment of certain complicated skin and soft tissue infections caused by gram-positive bacteria.
On September 6, 2007, Cubist Pharmaceuticals announced that the European Union has approved its antibacterial drug, Cubicin for the treatment of right heart endocarditis caused by Staphylococcus aureus infections and complicated skin and soft tissue infection related disease